SOURCE: Upstream Biosciences Inc.

July 16, 2007 09:00 ET

Upstream Biosciences Hires GendeLLindheim BioCom Partners as Agency of Record

Wall Street-Based PR & IR Boutique Specializes in Supporting Emerging Biotech Leaders

VANCOUVER, BC--(Marketwire - July 16, 2007) - Upstream Biosciences Inc. (OTCBB: UPBS), today announced it has hired GendeLLindheim BioCom Partners, LLC, as its communications agency of record. The firm, known as BioCom Partners, is a Manhattan-based public and investor relations boutique that specializes in supporting the growth of emerging and established biotechnology leaders. Principals Stephen Gendel and Barbara Lindheim bring decades of first-hand, professional expertise in media, financial and investor relations to their clients, who range from promising private firms to top-ranked industry bell weather stocks.

"Stephen and Barbara bring a tremendous depth of industry expertise, insight and contacts to our business," said Joel L. Bellenson, Chief Executive Officer of Upstream. "We believe their counsel will contribute significantly to our success as we advance our biomarker platform toward validation and commercialization."

Upstream Biosciences discovers and develops diagnostic and prognostic biomarkers. It currently is pursuing biomarkers to assess drug response, as well as for cancers of the liver, prostate, ovaries and thyroid. Upstream's diagnostics are intended to point the way toward optimal treatments for each patient and to enhance the accuracy of early detection of cancer.

"An advantage of a boutique firm is that we can target our practice to biotech companies such as Upstream that have highly innovative and commercially promising technology," noted Ms. Lindheim. "We are especially pleased by the opportunity to support Upstream and its novel diagnostic biomarker technology that has the potential to transform the promise of personalized medicine into a reality."

Founded in 2003, GendeLLindheim BioCom Partners is a full-service life sciences communications boutique distinguished by the hands-on expertise of its principals, its demonstrated ability to help young companies communicate complex technologies clearly and powerfully, and its commitment to delivering top quality professional services at reasonable rates. Stephen Gendel brings clients his knowledge and contacts from 25 years as an award-winning television reporter, including founding the health and science beat at business cable powerhouse CNBC. Barbara Lindheim brings her 15 years of expertise as a biopharmaceutical marketing and communications executive, along with the financial savvy and contacts she acquired along with her Harvard MBA. BioCom Partners is headquartered on Wall Street in New York City.

For more information, please contact: Samantha Haynes at 1-800-539-0289 or info@upstreambio.com

Media Contact: GendeLLindheim BioCom Partners, Barbara Lindheim: Tel: 212-918-4650

About Upstream Biosciences

Upstream Biosciences Inc. is an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response founded in 2004. Upstream discovers, develops, and licenses genetic-based diagnostics for cancer susceptibility and drug response. Upstream's proprietary data mining pipeline enables it to locate and analyze genetic variations in the regions of DNA 'upstream' of the gene. These 'gene switches' control gene expression, including the quantities and timing of the gene's production of the proteins that are important to disease status and drug response. For more information about the company please visit http://www.upstreambio.com.

Notice Regarding Forward-Looking Statements: This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) the appointment of GendeLLindheim BioCom Partners, LLC may bring a tremendous depth of industry expertise, insight and contacts to the business of the Company; (ii) the belief that such appointment will contribute significantly to the Company's success as the Company advances its biomarker platform toward validation and commercialization; (iii) the Company's diagnostics are intended to point the way toward optimal treatments for each patient and to enhance the accuracy of early detection of cancer; (iv) Upstream's technology has the potential to transform the promise of personalized medicine into reality; and (v) the Company may become an emerging leader in the field of diagnostics for cancer and the prediction of drug response. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that the Company does not execute its business plan; (ii) the inability of the Company to keep pace with technological advancements in the field of genetic diagnostics; (iii) the Company's inability to adequately protect its intellectual property or the Company's inadvertent infringement of third party intellectual property; (iv) the Company not being able to retain key employees; (v) competitors providing better or cheaper products and technologies; (vi) markets for the Company's products not developing as expected; (vii) the Company's inability to finance its operations or growth; (viii) inability to obtain all necessary government and regulatory approvals; and (ix) the inability to effectively market and commercialize the Company's technologies, including the establishment of viable relationships with third parties. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.

Contact Information

  • For more information, please contact:

    Samantha Haynes
    1-800-539-0289
    Email Contact

    Media Contact:

    GendeLLindheim BioCom Partners
    Barbara Lindheim
    Tel: 212-918-4650